SKAGI: Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun – vika 32

Skagi purchased 685,000 of its own shares in Vika 32 at an aggregate cost of ISK 12.78M (365,000 shares on 4.8.2026 at ISK 18.70 and 320,000 shares on 7.8.2026 at ISK 18.60), consistent with its repurchase program initiated 20 July 2026. The company targets up to 25M shares (~1.29% of issued share capital) with total buyback spending capped at ISK 350M through 15 September 2026. After these trades, Skagi holds 76.07M treasury shares (~3.92% of total share capital), versus ISK 67.49M cost basis for 3.58M shares previously repurchased.

Analysis

This is primarily a technical-positive, not a fundamental re-rate. In a small-cap with limited liquidity, a standing buyback can create a real price floor because it becomes a predictable marginal buyer, especially when the program has months left and the remaining authorization is still meaningful versus recent turnover. The near-term winner is existing equity holders; the bigger second-order effect is tighter free float, which can amplify upside on any good earnings or capital-update catalyst.

The risk is that the market eventually treats this as capital recycling rather than signal: if underlying underwriting/investment results do not improve, the multiple may not expand much beyond the mechanical EPS lift. Over 1-3 months, the key question is execution pace versus authorization; if daily repurchases slow or the company stops early, the bid can disappear quickly. Over 6-18 months, the stock only deserves a higher multiple if management can demonstrate that surplus capital is persistent and returns remain above the cost of equity.

Contrarian view: consensus will likely read this as straightforwardly bullish, but in regulated financials that can be an incomplete read. A buyback can also imply management sees no better reinvestment opportunity, which is positive for near-term per-share metrics but not necessarily for long-term franchise value. The thesis is falsified if the program is paused, the pace materially decelerates, or upcoming operating disclosures show capital is needed elsewhere.

Key Decisions for Investors

• Lean long on pullbacks into the remaining buyback window rather than chasing strength; the best risk/reward is likely over the next 2-6 weeks while the company remains a bid in the market.
• If you already own the name, hold through completion of the authorization only if liquidity stays supportive; take partial profits once the market prices in the end-of-program technical support.
• Watch for a slowdown in repurchase cadence or any regulatory/capital commentary at the next update; that is the clearest falsifier and should trigger de-risking.
• For relative-value exposure, prefer long the stock versus other local financials with no active capital-return program; the buyback should support relative performance as long as execution continues.